September 5th 2025
Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.
Use of First-Line Post-Protocol Immunotherapy Appears Low in Kidney Cell Carcinoma Clinical Trials
November 22nd 2021In a systemic review assessing the use of first-line post-protocol immunotherapy for patients with kidney cell carcinoma, investigators reported that use was low in randomized clinical trials among patients in the control group.
Adjuvant Pembrolizumab Approved by FDA for Treatment of Renal Cell Carcinoma in Certain Cases
November 18th 2021Patients with intermediate-risk and high-risk renal cell carcinoma had a statistically significant improvement in disease-free survival after being treated with pembrolizumab, which was approved by the FDA.
Nivolumab/Cabozantinib Combo Yielded Efficacy in Renal Cell Carcinoma Regardless of Nephrectomy
September 17th 2021Patients with renal cell carcinoma experienced a better overall survival when treated with nivolumab plus cabozantinib regardless of whether or not they underwent a nephrectomy previously.
Pembrolizumab Plus Lenvatinib Combo Approved for Treatment of First-Line Advanced RCC
August 12th 2021The combination of pembrolizumab plus lenvatinib received approval by the FDA in the first-line setting for patients with advanced renal cell carcinoma following the results of the phase 3 CLEAR trial.
FDA Grants Priority Review to BLA for Adjuvant Pembrolizumab in Certain Cases of RCC After Surgery
August 10th 2021A priority review to a biologics license application has been granted by the FDA for adjuvant pembrolizumab in certain populations of patients with renal cell carcinoma who have undergone surgery.
Lenvatinib Plus Pembrolizumab Demonstrates Antitumor Activity, Maintains Safety in Metastatic RCC
July 28th 2021The combination of lenvatinib plus pembrolizumab showed antitumor activity and a manageable safety profile for treatment-naïve or previously treated patients with metastatic renal cell carcinoma.